Hybrids of the hemiasterlin analogue taltobulin and the dolastatins are potent antimicrotubule agents

Journal of the American Chemical Society

Volumn 127, Issue 50, 2005, Pages 17667-17671

  Zask, Arie ^a   Kaplan, Joshua ^a   Musto, Sylvia ^a   Loganzo, Frank ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; DIMERS; ONCOLOGY; POLYMERIZATION; SYNTHESIS (CHEMICAL);

ANTIMICROTUBULE AGENTS; CANCER CHEMOTHERAPY; CLINICAL TRIALS; TRIPEPTIDE HEMIASTERLIN;

PROTEINS;

AURISTATIN PE; CEMADOTIN; DOLASTATIN; GLYCOPROTEIN P; ILX 651; SYNTHADOTIN; TALTOBULIN; TRIPEPTIDE; TUBULIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; MICROTUBULE; MICROTUBULE ASSEMBLY; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DEPSIPEPTIDES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; KB CELLS; MODELS, MOLECULAR; OLIGOPEPTIDES; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS; TUBULIN MODULATORS;

EID: 29344454439     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja053663v     Document Type: Article

References (19)

1. Rowinsky, E. K.; Tolcher, A. W. Antimicrotubule agents. In Cancer Principles and Practice, 6th ed.; Devita, V. T., Jr., Hellman, S., Rosenberger, S. A., Eds.; Lippincott Williams and Wilkins: Philadelphia. 2001; pp 431-452.
2. Jordan, M. A.; Wilson, L. Nat. Rev. Cancer 2004, 4, 253-265.
3. Beckers, T.; Mahboobi, S. Drugs Future 2003, 28, 767-785.
4. Gottesman, M. M. Annu. Rev. Med. 2002, 53, 615-627.
5. Bai R.; Pettit, G. R.; Hamel, E. J. Biol. Chem. 1990, 265, 17141-17149.
6. Bai, R.; Durso, N. A.; Sackett, D. L.; Hamel, E. Biochemistry 1999, 38, 14302-14310.
7. Ayral-Kaloustian, S.; Zask, A. Drugs Future 2005, 30, 254-260.
8. Loganzo, F.; et al. Cancer Res. 2003, 63, 1838-1845.
9. Zask, A.; et al. J. Med. Chem. 2004, 47, 4774-4786.
10. Hamel, E.; Covell, D. G. Curr. Med. Chem.: Anti-Cancer Agents 2002, 2, 19-53.
11. Mitra, A.; Sept, D. Biochemistry 2004, 43, 13955-13962.
12. Schmitt, J.; Bernd, M.; Kutscher, B.; Kessler, H. Bioorg. Med. Chem. Lett. 1998, 8, 385-388.
13. Poncet, J.; Busquet, M.; Roux, F.; Pierre, A.; Atassi, G.; Jouin, P. J. Med. Chem. 1998, 41, 1524-1530.
14. Zask, A.; et. al. Bioorg. Med. Chem. Lett. 2004, 14, 4353-4358.
15. Nieman, J. A.; Coleman, J. E.; Wallace, D. J.; Piers, E.; Lim, L. Y.; Roberge, M.; Andersen, R. J. J. Nat. Prod. 2003, 66, 183-199.
16. Poncet, J. Curr. Pharm. Des. 1999, 5, 139-162.
17. Pettit, G. R. Prog. Chem. Org. Nat. Prod. 1997, 70, 1-79.
18. Shiori, T.; Hayashi, K.; Hamada, Y. Tetrahedron 1993, 49, 1913-1924.
19. Bai, R.; Pettit, G. R.; Hamel, E. Biochem. Pharm. 1990, 40, 1859-1864.